5F-SDB-005 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 of 50 nM for human CB1 receptors, and 123 nM for human CB2 receptors. It was discovered during research into the related compound APICA which had been sold illicitly as “2NE1”. 5F-SDB-006 is the terminally fluorinated analog of SDB-006, just as STS-135 is the terminally fluorinated analog of APICA.
Active substances in 5F-SDB-005
Contains one gramm of min 98%+ pure 5F-SDB-005 per order unit.
Dosage of 5F-SDB-005
There is no recomended dose since 5F-SDB-005 is not for human consumption but is sold only as a research chemical for research purpose.
Effects of 5F-SDB-005 :
The clinical effects of most new designer drugs like 5F-SDB-005 can be described as either hallucinogenic, stimulant, or opioid-like. They may also have a combination of these effects due to designer side-chain substitutions.
Side effects of 5F-SDB-005
Like other designer drugs the use of 5F-SDB-005 can cause strong side effects; the substance is not clinically tested nor licensed in any way as a product for consumption! Therefore 5F-SDB-005 is NOT FOR HUMAN CONSUMPTION but for SCIENTIFICAL RESEARCH ONLY!
How to store 5F-SDB-005
Keep 5F-SDB-005 below 30 degrees Celsius. Store 5F-SDB-005 in the original package, protect from direct sunlight and moisture.
SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
The code number SDB-005 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM)